| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sepsis | 64 | 2026 | 401 | 10.350 |
Why?
|
| Shock, Septic | 49 | 2026 | 135 | 9.170 |
Why?
|
| Acute Kidney Injury | 28 | 2026 | 360 | 4.530 |
Why?
|
| Intensive Care Units, Pediatric | 45 | 2026 | 123 | 4.070 |
Why?
|
| Child | 156 | 2026 | 7681 | 3.730 |
Why?
|
| Critical Illness | 22 | 2026 | 360 | 2.860 |
Why?
|
| Child, Preschool | 93 | 2026 | 4000 | 2.720 |
Why?
|
| Infant | 82 | 2026 | 3329 | 2.500 |
Why?
|
| Systemic Inflammatory Response Syndrome | 21 | 2023 | 60 | 2.300 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 15 | 2025 | 977 | 2.130 |
Why?
|
| Multiple Organ Failure | 14 | 2024 | 63 | 1.950 |
Why?
|
| Anti-Bacterial Agents | 13 | 2025 | 876 | 1.760 |
Why?
|
| Adolescent | 82 | 2026 | 10081 | 1.680 |
Why?
|
| Hospital Mortality | 19 | 2024 | 518 | 1.500 |
Why?
|
| Biomarkers | 35 | 2026 | 2016 | 1.470 |
Why?
|
| Critical Care | 14 | 2025 | 462 | 1.270 |
Why?
|
| Humans | 175 | 2026 | 97898 | 1.220 |
Why?
|
| Hypotension | 2 | 2020 | 76 | 1.140 |
Why?
|
| Retrospective Studies | 54 | 2026 | 10953 | 1.120 |
Why?
|
| Anti-Infective Agents | 3 | 2023 | 87 | 1.040 |
Why?
|
| Male | 105 | 2026 | 47001 | 1.000 |
Why?
|
| Kidney Diseases | 4 | 2023 | 311 | 0.990 |
Why?
|
| Fluid Therapy | 6 | 2026 | 68 | 0.940 |
Why?
|
| Time-to-Treatment | 3 | 2024 | 156 | 0.920 |
Why?
|
| Female | 100 | 2026 | 51470 | 0.910 |
Why?
|
| Heart Arrest | 5 | 2025 | 315 | 0.910 |
Why?
|
| Vancomycin | 4 | 2022 | 78 | 0.890 |
Why?
|
| Severity of Illness Index | 24 | 2026 | 2008 | 0.860 |
Why?
|
| Prospective Studies | 37 | 2026 | 4799 | 0.860 |
Why?
|
| Respiratory Insufficiency | 8 | 2022 | 204 | 0.840 |
Why?
|
| Practice Guidelines as Topic | 6 | 2026 | 1108 | 0.830 |
Why?
|
| Infant, Newborn | 26 | 2026 | 2529 | 0.810 |
Why?
|
| Cytokines | 7 | 2022 | 889 | 0.800 |
Why?
|
| Immunocompromised Host | 2 | 2024 | 139 | 0.790 |
Why?
|
| Intensive Care Units | 8 | 2023 | 473 | 0.770 |
Why?
|
| Bacterial Infections | 3 | 2020 | 184 | 0.740 |
Why?
|
| Hospitals, Pediatric | 13 | 2022 | 128 | 0.740 |
Why?
|
| Intubation, Intratracheal | 6 | 2023 | 160 | 0.720 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2019 | 443 | 0.720 |
Why?
|
| Water-Electrolyte Imbalance | 4 | 2025 | 16 | 0.700 |
Why?
|
| Shock | 3 | 2021 | 48 | 0.680 |
Why?
|
| Respiratory Tract Infections | 4 | 2025 | 111 | 0.650 |
Why?
|
| Risk Factors | 21 | 2024 | 6225 | 0.590 |
Why?
|
| Databases as Topic | 1 | 2019 | 96 | 0.570 |
Why?
|
| Extracorporeal Membrane Oxygenation | 4 | 2023 | 230 | 0.550 |
Why?
|
| Vaccination | 1 | 2020 | 323 | 0.530 |
Why?
|
| Water-Electrolyte Balance | 3 | 2026 | 70 | 0.520 |
Why?
|
| Research Design | 3 | 2020 | 650 | 0.510 |
Why?
|
| Adaptation, Psychological | 1 | 2018 | 190 | 0.500 |
Why?
|
| Heart Diseases | 1 | 2019 | 268 | 0.500 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2016 | 3 | 0.490 |
Why?
|
| Prognosis | 19 | 2026 | 4112 | 0.470 |
Why?
|
| Phenotype | 11 | 2026 | 2638 | 0.470 |
Why?
|
| Leukemia | 1 | 2018 | 308 | 0.470 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2018 | 658 | 0.470 |
Why?
|
| Hospitalization | 12 | 2025 | 982 | 0.460 |
Why?
|
| High-Frequency Ventilation | 2 | 2013 | 10 | 0.460 |
Why?
|
| Hydrogen Peroxide | 1 | 2016 | 173 | 0.460 |
Why?
|
| Respiration, Artificial | 10 | 2025 | 430 | 0.460 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2026 | 302 | 0.460 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2017 | 452 | 0.440 |
Why?
|
| Immunoglobulins, Intravenous | 4 | 2023 | 66 | 0.440 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 314 | 0.430 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2025 | 26 | 0.430 |
Why?
|
| Organ Dysfunction Scores | 4 | 2022 | 34 | 0.430 |
Why?
|
| Quality of Life | 3 | 2024 | 1891 | 0.420 |
Why?
|
| Transcriptome | 5 | 2025 | 820 | 0.420 |
Why?
|
| Lung Injury | 2 | 2025 | 61 | 0.420 |
Why?
|
| United States | 26 | 2026 | 8184 | 0.410 |
Why?
|
| Cross-Sectional Studies | 12 | 2026 | 2037 | 0.410 |
Why?
|
| Length of Stay | 11 | 2026 | 869 | 0.410 |
Why?
|
| Electronic Health Records | 3 | 2024 | 437 | 0.400 |
Why?
|
| Immunotherapy | 5 | 2025 | 821 | 0.380 |
Why?
|
| Communication | 1 | 2016 | 455 | 0.380 |
Why?
|
| Creatinine | 6 | 2026 | 312 | 0.360 |
Why?
|
| Proprotein Convertase 9 | 2 | 2023 | 37 | 0.360 |
Why?
|
| Cohort Studies | 13 | 2025 | 3202 | 0.350 |
Why?
|
| Noninvasive Ventilation | 2 | 2022 | 41 | 0.340 |
Why?
|
| Aftercare | 4 | 2025 | 91 | 0.340 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 341 | 0.340 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 337 | 0.330 |
Why?
|
| Emergencies | 1 | 2011 | 122 | 0.330 |
Why?
|
| Logistic Models | 10 | 2021 | 1273 | 0.330 |
Why?
|
| Time Factors | 9 | 2025 | 5557 | 0.330 |
Why?
|
| Precision Medicine | 3 | 2025 | 498 | 0.330 |
Why?
|
| Disease Models, Animal | 9 | 2024 | 2573 | 0.330 |
Why?
|
| Glomerular Filtration Rate | 3 | 2022 | 299 | 0.330 |
Why?
|
| Brain Diseases | 2 | 2022 | 174 | 0.330 |
Why?
|
| Trachea | 1 | 2011 | 246 | 0.320 |
Why?
|
| Genetic Therapy | 4 | 2024 | 373 | 0.320 |
Why?
|
| Interleukin-8 | 6 | 2026 | 90 | 0.320 |
Why?
|
| Blood Transfusion | 2 | 2022 | 179 | 0.320 |
Why?
|
| Nervous System Diseases | 2 | 2023 | 169 | 0.320 |
Why?
|
| Brain Injuries, Traumatic | 2 | 2024 | 132 | 0.300 |
Why?
|
| HSP70 Heat-Shock Proteins | 5 | 2017 | 119 | 0.300 |
Why?
|
| Risk Assessment | 13 | 2024 | 2581 | 0.300 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2021 | 220 | 0.300 |
Why?
|
| Betacoronavirus | 3 | 2020 | 286 | 0.290 |
Why?
|
| Drug Monitoring | 2 | 2021 | 166 | 0.280 |
Why?
|
| Hypothermia, Induced | 2 | 2021 | 94 | 0.280 |
Why?
|
| Microglia | 3 | 2024 | 131 | 0.280 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 646 | 0.280 |
Why?
|
| Prevalence | 11 | 2022 | 1384 | 0.270 |
Why?
|
| Algorithms | 5 | 2020 | 2000 | 0.270 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2021 | 109 | 0.270 |
Why?
|
| Chlorides | 2 | 2018 | 102 | 0.270 |
Why?
|
| Resuscitation | 3 | 2017 | 134 | 0.270 |
Why?
|
| Renal Replacement Therapy | 3 | 2026 | 46 | 0.260 |
Why?
|
| Global Health | 4 | 2017 | 215 | 0.260 |
Why?
|
| Databases, Factual | 8 | 2020 | 1094 | 0.260 |
Why?
|
| Young Adult | 15 | 2022 | 7507 | 0.260 |
Why?
|
| Cardiopulmonary Resuscitation | 4 | 2025 | 256 | 0.260 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2025 | 136 | 0.260 |
Why?
|
| Eicosapentaenoic Acid | 2 | 2024 | 22 | 0.260 |
Why?
|
| Emergency Service, Hospital | 3 | 2017 | 619 | 0.250 |
Why?
|
| Neoplasms | 2 | 2021 | 3340 | 0.250 |
Why?
|
| Docosahexaenoic Acids | 2 | 2024 | 35 | 0.250 |
Why?
|
| Matrix Metalloproteinase 8 | 5 | 2017 | 5 | 0.250 |
Why?
|
| Brain | 4 | 2025 | 2429 | 0.250 |
Why?
|
| Influenza, Human | 2 | 2023 | 357 | 0.240 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 77 | 0.240 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2021 | 1098 | 0.240 |
Why?
|
| Health Resources | 2 | 2018 | 80 | 0.240 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2021 | 332 | 0.240 |
Why?
|
| Glucocorticoids | 4 | 2023 | 370 | 0.240 |
Why?
|
| Neutrophils | 2 | 2025 | 345 | 0.240 |
Why?
|
| STAT1 Transcription Factor | 1 | 2026 | 60 | 0.240 |
Why?
|
| Age Factors | 6 | 2021 | 1960 | 0.240 |
Why?
|
| STAT3 Transcription Factor | 1 | 2026 | 91 | 0.230 |
Why?
|
| Pediatrics | 3 | 2016 | 421 | 0.230 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2018 | 21 | 0.230 |
Why?
|
| PPAR gamma | 1 | 2026 | 80 | 0.230 |
Why?
|
| Cyclonic Storms | 1 | 2025 | 8 | 0.230 |
Why?
|
| Amyloid beta-Peptides | 2 | 2024 | 250 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 5 | 2024 | 3607 | 0.220 |
Why?
|
| Cephalosporins | 1 | 2025 | 25 | 0.220 |
Why?
|
| Disease Progression | 4 | 2023 | 1609 | 0.220 |
Why?
|
| C-Reactive Protein | 3 | 2023 | 209 | 0.220 |
Why?
|
| Body Weight | 1 | 2026 | 455 | 0.220 |
Why?
|
| Pandemics | 5 | 2023 | 913 | 0.220 |
Why?
|
| Delirium | 2 | 2024 | 79 | 0.220 |
Why?
|
| Granzymes | 4 | 2017 | 96 | 0.220 |
Why?
|
| Thrombocytopenia | 2 | 2023 | 194 | 0.210 |
Why?
|
| Gene Regulatory Networks | 2 | 2025 | 337 | 0.210 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2026 | 700 | 0.210 |
Why?
|
| Mannose | 1 | 2024 | 13 | 0.210 |
Why?
|
| Mice, Transgenic | 3 | 2024 | 1605 | 0.210 |
Why?
|
| Caspases, Initiator | 1 | 2024 | 1 | 0.210 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2017 | 358 | 0.210 |
Why?
|
| Hypothermia | 2 | 2022 | 26 | 0.210 |
Why?
|
| Epilepsy, Post-Traumatic | 1 | 2024 | 1 | 0.210 |
Why?
|
| Complement Membrane Attack Complex | 2 | 2020 | 21 | 0.210 |
Why?
|
| Memory, Long-Term | 1 | 2024 | 32 | 0.210 |
Why?
|
| Animals | 23 | 2024 | 28907 | 0.200 |
Why?
|
| Vomiting | 2 | 2016 | 109 | 0.200 |
Why?
|
| Mice | 16 | 2024 | 12702 | 0.200 |
Why?
|
| Models, Statistical | 3 | 2020 | 600 | 0.200 |
Why?
|
| Gene Expression Profiling | 5 | 2025 | 1565 | 0.200 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2023 | 15 | 0.190 |
Why?
|
| Meningitis, Aseptic | 1 | 2023 | 6 | 0.190 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 1750 | 0.190 |
Why?
|
| Quality Improvement | 2 | 2026 | 520 | 0.190 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2024 | 65 | 0.190 |
Why?
|
| Extracellular Vesicles | 1 | 2024 | 57 | 0.190 |
Why?
|
| Dysbiosis | 1 | 2024 | 101 | 0.190 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2023 | 17 | 0.190 |
Why?
|
| Case-Control Studies | 7 | 2023 | 1995 | 0.190 |
Why?
|
| Europe | 3 | 2018 | 356 | 0.190 |
Why?
|
| Chemokine CCL3 | 3 | 2017 | 13 | 0.190 |
Why?
|
| Antigens, CD19 | 2 | 2021 | 90 | 0.190 |
Why?
|
| Lipids | 2 | 2024 | 293 | 0.190 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2022 | 21 | 0.190 |
Why?
|
| Isotonic Solutions | 2 | 2026 | 18 | 0.190 |
Why?
|
| Immunologic Factors | 2 | 2021 | 179 | 0.180 |
Why?
|
| Connective Tissue Diseases | 1 | 2023 | 76 | 0.180 |
Why?
|
| Muscle Proteins | 2 | 2000 | 131 | 0.180 |
Why?
|
| Blood Banks | 1 | 2022 | 6 | 0.180 |
Why?
|
| Osteonecrosis | 1 | 2022 | 20 | 0.180 |
Why?
|
| Interleukin-6 | 2 | 2026 | 282 | 0.180 |
Why?
|
| Machine Learning | 2 | 2023 | 406 | 0.180 |
Why?
|
| Treatment Outcome | 13 | 2026 | 9684 | 0.180 |
Why?
|
| Recovery of Function | 2 | 2021 | 371 | 0.180 |
Why?
|
| Insulin Resistance | 1 | 2024 | 391 | 0.180 |
Why?
|
| Nanoparticles | 1 | 2024 | 218 | 0.170 |
Why?
|
| Child, Hospitalized | 1 | 2022 | 38 | 0.170 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2023 | 403 | 0.170 |
Why?
|
| Interferon Type I | 1 | 2022 | 170 | 0.170 |
Why?
|
| Blood Specimen Collection | 1 | 2021 | 28 | 0.170 |
Why?
|
| Diet | 1 | 2024 | 468 | 0.170 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2021 | 57 | 0.170 |
Why?
|
| Odds Ratio | 5 | 2022 | 725 | 0.170 |
Why?
|
| Maze Learning | 1 | 2021 | 33 | 0.170 |
Why?
|
| Transfusion Reaction | 1 | 2021 | 15 | 0.170 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 85 | 0.170 |
Why?
|
| Neurons | 2 | 2021 | 1619 | 0.160 |
Why?
|
| Erythrocytes | 1 | 2022 | 242 | 0.160 |
Why?
|
| Fatty Acids | 1 | 2021 | 145 | 0.160 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2020 | 23 | 0.160 |
Why?
|
| Inflammation Mediators | 2 | 2020 | 164 | 0.160 |
Why?
|
| Fingers | 1 | 2020 | 54 | 0.160 |
Why?
|
| Vasoconstrictor Agents | 2 | 2020 | 71 | 0.160 |
Why?
|
| France | 1 | 2020 | 53 | 0.160 |
Why?
|
| Intubation | 1 | 2020 | 21 | 0.160 |
Why?
|
| Meningitis, Bacterial | 1 | 2020 | 9 | 0.160 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2000 | 5 | 0.160 |
Why?
|
| Mitochondria | 2 | 2014 | 647 | 0.160 |
Why?
|
| Exercise Test | 1 | 2021 | 158 | 0.160 |
Why?
|
| Nerve Tissue Proteins | 2 | 2000 | 512 | 0.160 |
Why?
|
| Hypoxia | 2 | 2023 | 681 | 0.160 |
Why?
|
| Oximetry | 1 | 2020 | 90 | 0.160 |
Why?
|
| Epidemiological Monitoring | 1 | 2020 | 43 | 0.150 |
Why?
|
| Antimicrobial Stewardship | 1 | 2020 | 27 | 0.150 |
Why?
|
| Sea Urchins | 1 | 2019 | 5 | 0.150 |
Why?
|
| Hyperlactatemia | 1 | 2019 | 1 | 0.150 |
Why?
|
| ROC Curve | 5 | 2024 | 793 | 0.150 |
Why?
|
| Thiamine | 1 | 2019 | 11 | 0.150 |
Why?
|
| Genetic Vectors | 5 | 2014 | 426 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2021 | 297 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2021 | 239 | 0.150 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 1567 | 0.150 |
Why?
|
| Anthracyclines | 1 | 2019 | 31 | 0.150 |
Why?
|
| Homeodomain Proteins | 2 | 2000 | 566 | 0.150 |
Why?
|
| Phospholipids | 1 | 2019 | 109 | 0.150 |
Why?
|
| Patient Readmission | 1 | 2023 | 425 | 0.150 |
Why?
|
| Staphylococcal Infections | 1 | 2022 | 287 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2024 | 604 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2021 | 264 | 0.140 |
Why?
|
| Patient Discharge | 4 | 2023 | 380 | 0.140 |
Why?
|
| Clinical Coding | 1 | 2019 | 23 | 0.140 |
Why?
|
| Oocytes | 1 | 2019 | 213 | 0.140 |
Why?
|
| Down Syndrome | 2 | 2016 | 54 | 0.140 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2013 | 321 | 0.140 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2024 | 1255 | 0.140 |
Why?
|
| Kidney | 2 | 2023 | 1121 | 0.140 |
Why?
|
| Syndrome | 2 | 2017 | 438 | 0.140 |
Why?
|
| Orexins | 1 | 2018 | 9 | 0.140 |
Why?
|
| Models, Theoretical | 3 | 2015 | 508 | 0.140 |
Why?
|
| Afibrinogenemia | 1 | 2018 | 2 | 0.140 |
Why?
|
| Macrophage Activation Syndrome | 1 | 2018 | 2 | 0.140 |
Why?
|
| Nutritional Status | 1 | 2018 | 83 | 0.140 |
Why?
|
| Cell Adhesion Molecules | 1 | 2019 | 184 | 0.140 |
Why?
|
| Ethical Review | 1 | 2018 | 8 | 0.140 |
Why?
|
| Malnutrition | 1 | 2018 | 39 | 0.140 |
Why?
|
| Chest Wall Oscillation | 1 | 2017 | 5 | 0.140 |
Why?
|
| Ethics Committees, Research | 1 | 2018 | 34 | 0.140 |
Why?
|
| Acute Lung Injury | 1 | 2019 | 73 | 0.130 |
Why?
|
| Registries | 2 | 2025 | 1120 | 0.130 |
Why?
|
| Endoplasmic Reticulum | 1 | 2019 | 257 | 0.130 |
Why?
|
| Brain Injuries | 1 | 2020 | 142 | 0.130 |
Why?
|
| Evidence-Based Medicine | 3 | 2026 | 478 | 0.130 |
Why?
|
| Emergency Medical Services | 1 | 2021 | 286 | 0.130 |
Why?
|
| Body Mass Index | 2 | 2018 | 851 | 0.130 |
Why?
|
| User-Computer Interface | 1 | 2019 | 194 | 0.130 |
Why?
|
| Comorbidity | 2 | 2018 | 1032 | 0.130 |
Why?
|
| Hemodynamics | 5 | 2021 | 745 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2014 | 849 | 0.130 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 158 | 0.130 |
Why?
|
| Metabolic Diseases | 1 | 2018 | 60 | 0.130 |
Why?
|
| Clinical Alarms | 1 | 2017 | 17 | 0.130 |
Why?
|
| Hippocampus | 1 | 2021 | 462 | 0.130 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2017 | 22 | 0.130 |
Why?
|
| Skin | 1 | 2020 | 591 | 0.130 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2017 | 59 | 0.130 |
Why?
|
| AIDS Vaccines | 2 | 2009 | 16 | 0.130 |
Why?
|
| Patient Care Bundles | 1 | 2017 | 22 | 0.130 |
Why?
|
| Textbooks as Topic | 1 | 2016 | 2 | 0.130 |
Why?
|
| Immunization, Secondary | 2 | 2009 | 42 | 0.120 |
Why?
|
| Postoperative Complications | 2 | 2019 | 2680 | 0.120 |
Why?
|
| Ultrasonography | 2 | 2021 | 720 | 0.120 |
Why?
|
| Antibodies, Viral | 4 | 2022 | 339 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 665 | 0.120 |
Why?
|
| Signal Transduction | 2 | 2026 | 3623 | 0.120 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2017 | 52 | 0.120 |
Why?
|
| Sleep Wake Disorders | 1 | 2018 | 139 | 0.120 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 223 | 0.120 |
Why?
|
| Heart | 1 | 2019 | 527 | 0.120 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2016 | 12 | 0.120 |
Why?
|
| Chest Pain | 1 | 2016 | 44 | 0.120 |
Why?
|
| Incidence | 4 | 2024 | 1777 | 0.120 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2016 | 63 | 0.120 |
Why?
|
| Orthomyxoviridae | 1 | 2016 | 46 | 0.120 |
Why?
|
| Sensitivity and Specificity | 5 | 2020 | 1944 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 74 | 0.110 |
Why?
|
| Steroids | 1 | 2016 | 168 | 0.110 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2017 | 145 | 0.110 |
Why?
|
| Factor IX | 2 | 2006 | 5 | 0.110 |
Why?
|
| Adult | 11 | 2023 | 29458 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 1394 | 0.110 |
Why?
|
| Virus Diseases | 1 | 2016 | 83 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 194 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 557 | 0.110 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2015 | 53 | 0.110 |
Why?
|
| Survival of Motor Neuron 1 Protein | 1 | 2014 | 7 | 0.110 |
Why?
|
| Dependovirus | 1 | 2014 | 38 | 0.110 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2014 | 28 | 0.110 |
Why?
|
| Models, Biological | 2 | 2019 | 1805 | 0.110 |
Why?
|
| Survival Rate | 4 | 2021 | 2040 | 0.100 |
Why?
|
| Cross Infection | 1 | 2015 | 155 | 0.100 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2013 | 37 | 0.100 |
Why?
|
| Genotype | 3 | 2026 | 1888 | 0.100 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 155 | 0.100 |
Why?
|
| Survival Analysis | 4 | 2019 | 1527 | 0.100 |
Why?
|
| Recurrence | 1 | 2017 | 1254 | 0.100 |
Why?
|
| Proteolysis | 1 | 2014 | 129 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2017 | 831 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2015 | 345 | 0.100 |
Why?
|
| Macrophage Activation | 1 | 2013 | 53 | 0.100 |
Why?
|
| Spinal Cord | 1 | 2014 | 243 | 0.100 |
Why?
|
| Stroke | 1 | 2023 | 1154 | 0.100 |
Why?
|
| Clinical Decision-Making | 1 | 2015 | 304 | 0.100 |
Why?
|
| Immune System Diseases | 1 | 2013 | 25 | 0.100 |
Why?
|
| Glasgow Coma Scale | 2 | 2024 | 76 | 0.100 |
Why?
|
| Protein Kinases | 1 | 2014 | 212 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 188 | 0.090 |
Why?
|
| Lipocalin-2 | 2 | 2025 | 42 | 0.090 |
Why?
|
| Cystatin C | 2 | 2025 | 29 | 0.090 |
Why?
|
| Antibodies, Bispecific | 1 | 2013 | 51 | 0.090 |
Why?
|
| Cell Nucleus | 1 | 2014 | 615 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2017 | 2063 | 0.090 |
Why?
|
| Gagging | 1 | 2011 | 1 | 0.090 |
Why?
|
| Metapneumovirus | 1 | 2011 | 3 | 0.090 |
Why?
|
| Paramyxoviridae Infections | 1 | 2011 | 5 | 0.090 |
Why?
|
| Subcutaneous Emphysema | 1 | 2011 | 8 | 0.090 |
Why?
|
| Respiratory Aspiration | 1 | 2011 | 6 | 0.090 |
Why?
|
| Mediastinal Emphysema | 1 | 2011 | 6 | 0.090 |
Why?
|
| Clinical Protocols | 3 | 2017 | 156 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2014 | 255 | 0.090 |
Why?
|
| Neuroimaging | 2 | 2024 | 143 | 0.090 |
Why?
|
| Healthcare Disparities | 3 | 2026 | 540 | 0.090 |
Why?
|
| Philadelphia | 3 | 2017 | 27 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2024 | 1778 | 0.090 |
Why?
|
| Positive-Pressure Respiration | 1 | 2011 | 50 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 2783 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 2 | 2024 | 183 | 0.080 |
Why?
|
| Immunomodulation | 2 | 2021 | 65 | 0.080 |
Why?
|
| Autistic Disorder | 1 | 2011 | 155 | 0.080 |
Why?
|
| Equipment Design | 1 | 2011 | 425 | 0.080 |
Why?
|
| Chromatography, Liquid | 2 | 2021 | 102 | 0.080 |
Why?
|
| Infusions, Intravenous | 2 | 2025 | 402 | 0.080 |
Why?
|
| Endothelial Cells | 2 | 2023 | 500 | 0.080 |
Why?
|
| Rats | 3 | 2022 | 4070 | 0.080 |
Why?
|
| Bronchoscopy | 1 | 2011 | 182 | 0.080 |
Why?
|
| Acute Disease | 3 | 2018 | 857 | 0.080 |
Why?
|
| Adenoviruses, Simian | 1 | 2009 | 2 | 0.080 |
Why?
|
| Radiography | 1 | 2011 | 762 | 0.080 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2009 | 10 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3606 | 0.080 |
Why?
|
| Stroke Volume | 2 | 2023 | 464 | 0.070 |
Why?
|
| Gene Expression Regulation | 2 | 2015 | 2019 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 4023 | 0.070 |
Why?
|
| Seizures | 1 | 2011 | 318 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2022 | 968 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 762 | 0.070 |
Why?
|
| Oxygen | 1 | 2013 | 772 | 0.070 |
Why?
|
| Adenoviruses, Human | 2 | 2009 | 41 | 0.070 |
Why?
|
| Morbidity | 2 | 2020 | 162 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 889 | 0.070 |
Why?
|
| Lung | 2 | 2025 | 1406 | 0.070 |
Why?
|
| Decision Trees | 2 | 2019 | 63 | 0.070 |
Why?
|
| Neutralization Tests | 2 | 2022 | 74 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2019 | 340 | 0.060 |
Why?
|
| Animals, Newborn | 2 | 2021 | 525 | 0.060 |
Why?
|
| Angiopoietin-2 | 1 | 2026 | 23 | 0.060 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 1850 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 2892 | 0.060 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2025 | 11 | 0.060 |
Why?
|
| Inflammation | 2 | 2024 | 1122 | 0.060 |
Why?
|
| Autopsy | 1 | 2025 | 131 | 0.060 |
Why?
|
| Cell Survival | 2 | 2021 | 1016 | 0.060 |
Why?
|
| Obesity | 2 | 2023 | 1061 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 1110 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2026 | 2558 | 0.060 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2025 | 25 | 0.060 |
Why?
|
| Interleukin-18 | 1 | 2025 | 27 | 0.060 |
Why?
|
| Hepatocytes | 1 | 2006 | 137 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2020 | 287 | 0.050 |
Why?
|
| Dietary Sucrose | 1 | 2024 | 14 | 0.050 |
Why?
|
| Cause of Death | 2 | 2017 | 278 | 0.050 |
Why?
|
| Hemophilia B | 1 | 2004 | 5 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2025 | 150 | 0.050 |
Why?
|
| Antagomirs | 1 | 2024 | 3 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2026 | 479 | 0.050 |
Why?
|
| Adenovirus E1 Proteins | 1 | 2003 | 1 | 0.050 |
Why?
|
| HIV Antigens | 1 | 2003 | 2 | 0.050 |
Why?
|
| Gene Products, gag | 1 | 2003 | 10 | 0.050 |
Why?
|
| Intervertebral Disc | 1 | 2024 | 32 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2024 | 84 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2000 | 1254 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 3272 | 0.050 |
Why?
|
| Back Pain | 1 | 2024 | 76 | 0.050 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2023 | 13 | 0.050 |
Why?
|
| Endoglin | 1 | 2023 | 22 | 0.050 |
Why?
|
| Angiopoietin-1 | 1 | 2023 | 7 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2024 | 285 | 0.050 |
Why?
|
| Low Back Pain | 1 | 2024 | 62 | 0.050 |
Why?
|
| PAX7 Transcription Factor | 2 | 2000 | 5 | 0.050 |
Why?
|
| Academic Medical Centers | 2 | 2017 | 407 | 0.050 |
Why?
|
| Crowding | 1 | 2023 | 11 | 0.050 |
Why?
|
| NF-kappa B p52 Subunit | 1 | 2022 | 3 | 0.050 |
Why?
|
| Renin | 1 | 2023 | 67 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2023 | 53 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2023 | 63 | 0.050 |
Why?
|
| Family Characteristics | 1 | 2023 | 52 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 1009 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2023 | 136 | 0.050 |
Why?
|
| Masks | 1 | 2023 | 31 | 0.050 |
Why?
|
| Thrombomodulin | 1 | 2022 | 10 | 0.050 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2026 | 268 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2022 | 77 | 0.050 |
Why?
|
| Immunoassay | 1 | 2022 | 102 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2022 | 123 | 0.050 |
Why?
|
| Haploinsufficiency | 1 | 2022 | 72 | 0.050 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2022 | 36 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 65 | 0.040 |
Why?
|
| Viral Envelope Proteins | 1 | 2022 | 80 | 0.040 |
Why?
|
| Cannula | 1 | 2022 | 55 | 0.040 |
Why?
|
| Blood Component Transfusion | 1 | 2021 | 13 | 0.040 |
Why?
|
| Seasons | 1 | 2023 | 252 | 0.040 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2021 | 28 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 213 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2022 | 71 | 0.040 |
Why?
|
| Italy | 1 | 2021 | 113 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2000 | 1717 | 0.040 |
Why?
|
| Sucrose | 1 | 2021 | 63 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 3021 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2022 | 286 | 0.040 |
Why?
|
| Transfusion-Related Acute Lung Injury | 1 | 2021 | 1 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2021 | 24 | 0.040 |
Why?
|
| Canada | 1 | 2021 | 210 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 156 | 0.040 |
Why?
|
| Physical Conditioning, Animal | 1 | 2021 | 19 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2021 | 38 | 0.040 |
Why?
|
| Antifibrinolytic Agents | 1 | 2021 | 49 | 0.040 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 100 | 0.040 |
Why?
|
| Age Distribution | 1 | 2021 | 208 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 107 | 0.040 |
Why?
|
| Spatial Memory | 1 | 2021 | 30 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2003 | 822 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 236 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2020 | 69 | 0.040 |
Why?
|
| Liver | 2 | 2021 | 1229 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2022 | 182 | 0.040 |
Why?
|
| Piperacillin | 1 | 2020 | 8 | 0.040 |
Why?
|
| Penicillanic Acid | 1 | 2020 | 12 | 0.040 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 26 | 0.040 |
Why?
|
| Propensity Score | 1 | 2021 | 213 | 0.040 |
Why?
|
| Erythrocyte Count | 1 | 2020 | 21 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2020 | 43 | 0.040 |
Why?
|
| Streptococcus agalactiae | 1 | 2020 | 13 | 0.040 |
Why?
|
| APACHE | 1 | 2020 | 24 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 153 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 661 | 0.040 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2000 | 30 | 0.040 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 24 | 0.040 |
Why?
|
| Temperature | 1 | 2022 | 442 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2020 | 94 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2000 | 51 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2022 | 423 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2022 | 446 | 0.040 |
Why?
|
| Punctures | 1 | 2019 | 29 | 0.040 |
Why?
|
| Neurogenesis | 1 | 2021 | 93 | 0.040 |
Why?
|
| Age of Onset | 1 | 2021 | 367 | 0.040 |
Why?
|
| Ligation | 1 | 2019 | 55 | 0.040 |
Why?
|
| Streptococcal Infections | 1 | 2020 | 57 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2020 | 214 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 214 | 0.040 |
Why?
|
| HIV Infections | 1 | 2009 | 1018 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 577 | 0.040 |
Why?
|
| Fungi | 1 | 2020 | 70 | 0.040 |
Why?
|
| Nephritis, Interstitial | 1 | 2020 | 44 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 373 | 0.040 |
Why?
|
| Rhabdomyosarcoma | 1 | 1999 | 44 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 169 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2020 | 399 | 0.040 |
Why?
|
| Viruses | 1 | 2020 | 64 | 0.040 |
Why?
|
| Cecum | 1 | 2019 | 78 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2000 | 107 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2023 | 540 | 0.040 |
Why?
|
| Sarcoma, Ewing | 1 | 1999 | 42 | 0.040 |
Why?
|
| Inpatients | 1 | 2023 | 367 | 0.040 |
Why?
|
| Osteopontin | 1 | 2019 | 48 | 0.040 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2020 | 74 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2024 | 789 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2019 | 95 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 175 | 0.040 |
Why?
|
| Insulin | 1 | 2024 | 1224 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2000 | 245 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2024 | 730 | 0.040 |
Why?
|
| South America | 1 | 2018 | 38 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 424 | 0.040 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2020 | 130 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 109 | 0.040 |
Why?
|
| Orexin Receptor Antagonists | 1 | 2018 | 1 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 480 | 0.030 |
Why?
|
| Hyperphagia | 1 | 2018 | 36 | 0.030 |
Why?
|
| Ghrelin | 1 | 2018 | 31 | 0.030 |
Why?
|
| Coma | 1 | 2018 | 44 | 0.030 |
Why?
|
| Microbiota | 1 | 2024 | 467 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2019 | 117 | 0.030 |
Why?
|
| North America | 1 | 2018 | 210 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 237 | 0.030 |
Why?
|
| Leptin | 1 | 2018 | 101 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2020 | 305 | 0.030 |
Why?
|
| Ohio | 1 | 2017 | 43 | 0.030 |
Why?
|
| Neurosurgery | 1 | 2020 | 148 | 0.030 |
Why?
|
| Calcitonin | 1 | 2017 | 41 | 0.030 |
Why?
|
| International Cooperation | 1 | 2017 | 132 | 0.030 |
Why?
|
| Serum Amyloid A Protein | 1 | 2017 | 26 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2018 | 130 | 0.030 |
Why?
|
| Acidosis | 1 | 2017 | 53 | 0.030 |
Why?
|
| Vital Signs | 1 | 2017 | 36 | 0.030 |
Why?
|
| Kinetics | 1 | 2019 | 1476 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2019 | 393 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2024 | 1445 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 62 | 0.030 |
Why?
|
| Sodium Chloride | 1 | 2017 | 83 | 0.030 |
Why?
|
| Chemokines, CC | 1 | 2016 | 36 | 0.030 |
Why?
|
| Platelet Count | 1 | 2016 | 94 | 0.030 |
Why?
|
| Spleen | 1 | 2017 | 375 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 38 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 471 | 0.030 |
Why?
|
| Nasopharynx | 1 | 2016 | 51 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 263 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 1999 | 409 | 0.030 |
Why?
|
| Myeloblastin | 1 | 2015 | 5 | 0.030 |
Why?
|
| Bacteria | 1 | 2020 | 545 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2016 | 113 | 0.030 |
Why?
|
| Anesthesia | 1 | 2017 | 175 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 90 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 122 | 0.030 |
Why?
|
| Motor Activity | 1 | 2017 | 328 | 0.030 |
Why?
|
| Mathematical Computing | 1 | 2015 | 20 | 0.030 |
Why?
|
| Pan troglodytes | 2 | 2009 | 203 | 0.030 |
Why?
|
| Melanoma | 1 | 1999 | 524 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 301 | 0.030 |
Why?
|
| Injections, Epidural | 1 | 2014 | 9 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 2015 | 42 | 0.030 |
Why?
|
| Glucose | 1 | 2018 | 703 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2014 | 111 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 154 | 0.030 |
Why?
|
| Fever | 1 | 2015 | 121 | 0.030 |
Why?
|
| Pneumothorax | 1 | 2015 | 51 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2017 | 1027 | 0.030 |
Why?
|
| Chaperonin 60 | 1 | 2014 | 7 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 3246 | 0.030 |
Why?
|
| Transgenes | 1 | 2014 | 173 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2014 | 161 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 660 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2017 | 398 | 0.030 |
Why?
|
| Consensus | 1 | 2015 | 315 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2014 | 380 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 579 | 0.030 |
Why?
|
| Sleep | 1 | 2018 | 465 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2014 | 161 | 0.030 |
Why?
|
| Brain Stem | 1 | 2014 | 167 | 0.030 |
Why?
|
| Respiratory Rate | 1 | 2013 | 25 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 2017 | 315 | 0.020 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2013 | 18 | 0.020 |
Why?
|
| Heat-Shock Response | 1 | 2014 | 55 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1536 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 256 | 0.020 |
Why?
|
| Sex Factors | 1 | 2017 | 1137 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 2373 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2016 | 234 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 836 | 0.020 |
Why?
|
| Motor Neurons | 1 | 2014 | 193 | 0.020 |
Why?
|
| Mortality | 1 | 2014 | 158 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2014 | 679 | 0.020 |
Why?
|
| Sirolimus | 1 | 2014 | 182 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2013 | 239 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 800 | 0.020 |
Why?
|
| Mutation | 1 | 2004 | 4396 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 902 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 718 | 0.020 |
Why?
|
| Burns | 1 | 2013 | 150 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2015 | 382 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 571 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1946 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 1320 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2015 | 470 | 0.020 |
Why?
|
| Simian Immunodeficiency Virus | 1 | 2009 | 22 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2014 | 2206 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2009 | 75 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2009 | 187 | 0.020 |
Why?
|
| HIV-1 | 1 | 2009 | 179 | 0.020 |
Why?
|
| Apoptosis | 1 | 2014 | 1752 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2009 | 466 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 505 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 281 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 2006 | 174 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2006 | 218 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2006 | 155 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2006 | 340 | 0.010 |
Why?
|
| Codon, Nonsense | 1 | 2004 | 48 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2003 | 23 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2003 | 63 | 0.010 |
Why?
|
| Vaccines, DNA | 1 | 2003 | 20 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 2003 | 20 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2004 | 172 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2003 | 99 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2006 | 386 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2006 | 358 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2004 | 302 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2003 | 519 | 0.010 |
Why?
|
| PAX3 Transcription Factor | 1 | 1999 | 11 | 0.010 |
Why?
|
| RNA | 1 | 2004 | 595 | 0.010 |
Why?
|
| Paired Box Transcription Factors | 1 | 1999 | 50 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 2482 | 0.010 |
Why?
|
| Plasmids | 1 | 1999 | 275 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1999 | 403 | 0.010 |
Why?
|
| Exons | 1 | 1999 | 451 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 1028 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 1999 | 224 | 0.010 |
Why?
|
| Aged | 1 | 2016 | 21704 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1999 | 2002 | 0.010 |
Why?
|
| Base Sequence | 1 | 1999 | 2222 | 0.010 |
Why?
|
| Middle Aged | 1 | 2016 | 29358 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1999 | 2893 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 1133 | 0.010 |
Why?
|
| Models, Genetic | 1 | 1999 | 1005 | 0.010 |
Why?
|